Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

by Taylor, Kirsten I. , Stocchi, Fabrizio , Lindemann, Michael , Boyd, James T. , Bonni, Azad , Russell, David S. , Rukina, Daria , Vogt, Annamarie , Volkova-Volkmar, Ekaterina , Pavese, Nicola , Lipsmeier, Florian , Simuni, Tanya , Mollenhauer, Brit , Pagano, Gennaro , Marchesi, Maddalena , Marek, Kenneth , Kerchner, Geoffrey A. , Postuma, Ronald B. , Dukart, Juergen , Pross, Nathalie , Dziadek, Sebastian , Boess, Frank G. , Doody, Rachelle , Azulay, Jean-Philippe , Kustermann, Thomas , Anzures-Cabrera, Judith , López-Manzanares, Lydia , Nikolcheva, Tania , Umbricht, Daniel , Fontoura, Paulo , Poewe, Werner , Finch, Rebecca , Luquin, María R. , Boulay, Anne , Hahn, Andrea , Holiga, Štefan , Nicholas, Anthony P. , Hauser, Robert A. , D’Urso, Giulia , Ricci, Benedicte , Gasser, Thomas , Svoboda, Hanno , Zanigni, Stefano , Britschgi, Markus , Monnet, Annabelle

in Activities of daily living / Aging / Aging General / alpha-Synuclein - antagonists & inhibitors / Antibodies, Monoclonal, Humanized - therapeutic use / Antiparkinson Agents - therapeutic use / Clinical outcomes / Computed tomography / Dopamine / Dopamine Plasma Membrane Transport Proteins - therapeutic use / Dopamine transporter / Double-Blind Method / Geriatrics / Humans / Intravenous administration / Life Sciences / Monoclonal antibodies / Movement disorders / Neurodegenerative diseases / Neurology / Neurosurgery / Parkinson Disease / Parkinson Disease - drug therapy / Parkinson's disease / Pathogenesis / Placebos / Putamen / Single photon emission computed tomography / Synuclein / Treatment Outcome

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

2022

Confirm

Do you wish to request the book?

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Taylor, Kirsten I.,

Stocchi, Fabrizio,

Lindemann, Michael,

Boyd, James T.,

Bonni, Azad,

Russell, David S.,

Rukina, Daria,

Vogt, Annamarie,

Volkova-Volkmar, Ekaterina,

Pavese, Nicola,

Lipsmeier, Florian,

Simuni, Tanya,

Mollenhauer, Brit,

Pagano, Gennaro,

Marchesi, Maddalena,

Marek, Kenneth,

Kerchner, Geoffrey A.,

Postuma, Ronald B.,

Dukart, Juergen,

Pross, Nathalie,

Dziadek, Sebastian,

Boess, Frank G.,

Doody, Rachelle,

Azulay, Jean-Philippe,

Kustermann, Thomas,

Anzures-Cabrera, Judith,

López-Manzanares, Lydia,

Nikolcheva, Tania,

Umbricht, Daniel,

Fontoura, Paulo,

Poewe, Werner,

Finch, Rebecca,

Luquin, María R.,

Boulay, Anne,

Hahn, Andrea,

Holiga, Štefan,

Nicholas, Anthony P.,

Hauser, Robert A.,

D’Urso, Giulia,

Ricci, Benedicte,

Gasser, Thomas,

Svoboda, Hanno,

Zanigni, Stefano,

Britschgi, Markus,

Monnet, Annabelle

2022

Overview

Prasinezumab is a monoclonal antibody to α-synuclein, a protein involved in the pathogenesis of Parkinson’s disease. In a placebo-controlled trial, prasinezumab did not slow the progression of disease over a period of 52 weeks.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Activities of daily living

/ Aging

/ Aging General

/ alpha-Synuclein - antagonists & inhibitors

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ Antiparkinson Agents - therapeutic use

/ Clinical outcomes